Literature DB >> 10030749

Iodine-131 human-mouse chimeric Fab monoclonal antibody A7 guided surgery for colorectal cancer patients: a pilot study.

K Yamamoto1, K Kitamura, S Nishida, D Ichikawa, K Okamoto, T Yamaguchi, T Takahashi.   

Abstract

This study was conducted to determine the clinical usefulness of radioimmunoguided surgery (RIGS) using human-mouse chimeric Fab monoclonal antibody A7 (ch-Fab-A7) for colorectal cancer patients. Ten colorectal cancer patients were given iodine-131-labeled ch-Fab-A7 intravenously (i.v.) 2 to 7 days prior to RIGS. The RIGS was carried out using a portable gamma detecting probe (GDP). Tumor localization was identified by GDP intraoperatively in 4 of the ten patients, while liver metastasis and lymph node metastasis were identified in 2 patients and 1 patient, respectively. The GDP revealed tumor/surrounding tissue radio(gamma)count ratios of 1.5 or greater in 8 of the ten resected tumors. Although RIGS using ch-Fab-A7 is a promising tool for intraoperatively identifying the tumor localization of colorectal cancer, 125I, rather than 131I, should be used as a tracer for RIGS to enhance the accuracy of ch-Fab-A7.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10030749     DOI: 10.1007/BF02482249

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  14 in total

1.  Immunochemical characterization of the antigen recognized by the murine monoclonal antibody A7 against human colorectal cancer.

Authors:  K Kitamura; T Takahashi; T Yamaguchi; T Yokota; A Noguchi; T Amagai; J Imanishi
Journal:  Tohoku J Exp Med       Date:  1989-02       Impact factor: 1.848

2.  Intra-abdominal recurrence of colorectal cancer detected by radioimmunoguided surgery (RIGS system).

Authors:  A Sardi; M Workman; C Mojzisik; G Hinkle; C Nieroda; E W Martin
Journal:  Arch Surg       Date:  1989-01

3.  Radioimmunoguided surgery using monoclonal antibody.

Authors:  E W Martin; C M Mojzisik; G H Hinkle; J Sampsel; M A Siddiqi; S E Tuttle; B Sickle-Santanello; D Colcher; M O Thurston; J G Bell
Journal:  Am J Surg       Date:  1988-11       Impact factor: 2.565

4.  Role of B72.3 iodine 125-labeled monoclonal antibody in colorectal cancer detection by radioimmunoguided surgery.

Authors:  V Di Carlo; F Badellino; M Stella; P De Nardi; F Fazio; P Percivale; S Bertoglio; F Schenone; A Benevento; G Carcano
Journal:  Surgery       Date:  1994-02       Impact factor: 3.982

5.  Staging of carcinoma of the breast using a hand-held gamma detecting probe and monoclonal antibody B72.3.

Authors:  C A Nieroda; C Mojzisik; A Sardi; W B Farrar; G Hinkle; M A Siddiqi; P J Ferrara; A James; J Schlom; M O Thurston
Journal:  Surg Gynecol Obstet       Date:  1989-07

6.  Radioimmunoguided surgery challenges traditional decision making in patients with primary colorectal cancer.

Authors:  M W Arnold; S Schneebaum; A Berens; C Mojzisik; G Hinkle; E W Martin
Journal:  Surgery       Date:  1992-10       Impact factor: 3.982

7.  Intraoperative detection of occult colon cancer micrometastases using 125 I-radiolabled monoclonal antibody CC49.

Authors:  R J Cote; D P Houchens; C L Hitchcock; A D Saad; R G Nines; J K Greenson; S Schneebaum; M W Arnold; E W Martin
Journal:  Cancer       Date:  1996-02-15       Impact factor: 6.860

8.  Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer.

Authors:  A M Cohen; E W Martin; I Lavery; J Daly; A Sardi; D Aitken; K Bland; C Mojzisik; G Hinkle
Journal:  Arch Surg       Date:  1991-03

9.  Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab')2, and Fab in tumors.

Authors:  K Fujimori; D G Covell; J E Fletcher; J N Weinstein
Journal:  Cancer Res       Date:  1989-10-15       Impact factor: 12.701

10.  Pharmacokinetic analysis of the monoclonal antibody A7-neocarzinostatin conjugate administered to nude mice.

Authors:  K Kitamura; T Takahashi; A Noguchi; H Tsurumi; K Takashina; J Okuzumi; T Yamaguchi
Journal:  Tohoku J Exp Med       Date:  1991-07       Impact factor: 1.848

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.